TRYPSIN VI is a serine protease complex, containing trypsin (EC 220.127.116.11) and chymotrypsin(EC 18.104.22.168), obtained from the porcine pancreas by Neova Technologies Inc. The serine protease complex is intended to be used for hydrolysis of whey proteins employed as ingredients of infant formulae and follow-on formulae.
Trypsin and chymotrypsin’s primary function in the human body is the digestion of proteins. These naturally occurring pancreatic proteins play an important role in the digestion of food in the human body. This functional property makes them effective when used in food applications for the purpose of hydrolyzing proteins.
TRYPSIN VI is an enzyme preparation containing both trypsin and chymotrypsin specifically designed for food and OTC pharmaceutical applications.
Trypsin has extensive applications due to its fundamental physiological function which is the same natural process as the human digestive system. Trypsin has effective uses in foods and pharmaceuticals, as well as in tissue dissociation, cell harvesting, and microbiological media.
TRYPSIN VI is ideal for applications in foods. The addition of TRYPSIN VI to food products can result in enhanced properties such as improved whip and taste, increased digestibility, and reduced allergenicity. Typical applications include:
- Partial digestion of milk and whey proteins;
- Hypoallergenic food production;
- Facilitate rapid absorption of nutrients;
- Meat and seafood tenderizing;
TRYPSIN VI is an effective ingredient used in nutraceuticals. It has been used in human and veterinarian digestive supplements and anti-inflammatory treatments.
Specifications (USP units/mg):
Trypsin Activity Minimum 2500
Chymotrypsin Activity Minimum 250
No Warranty: The information contained herein is provided in good faith and, to the best of our knowledge, is true and correct. However, no warranty or guarantee is implied or inferred and the information may be subject to change without further notice. Neova Technologies Inc.’s products are sold with the understanding that the purchaser will conduct tests to determine the suitability of these products for their particular use.
Bioseutica® is proud to inform that the European Food Safety Authority (EFSA) has just issued its scientific opinions on two applications submitted by NEOVA Technologies Inc (a BIOSEUTICA group company) related to the food enzymes
- trypsin and chymotrypsin from porcine pancreas (our Brand name TRYPSIN VI)
- trypsin, chymotrypsin, elastase and carboxypeptidase from porcine pancreas (our Brand name TRYPSIN SE)
The EFSA conclusions for the 2 enzymes are:
“Based on the origin of the food enzyme from edible parts of animals, the data provided by the applicant, supported by the evaluation of clinical studies with pharmaceutical preparations based on pancreatic enzymes, the Panel concluded that the porcine pancreatic enzymes do not give rise to safety concern under the intended conditions of use.”
Access to the 2 scientific opinions published on the EFSA Journal Vol. 19, No. 1, January 2021 is freely available here.
Based on these EFSA safety evaluations, the 2 food enzymes will be approved by the European Commission by means of their inclusion into the Union list of food enzymes, expected in 2023.
These positive opinions are a confirmation of the commitment the Bioseutica group has to the quality and safety of its products, as well as to our dedication to service to our customers and end-users.